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Previous studies have demonstrated immunosuppressive and anti-inflammatory
effects of nicotine, including in the experimental autoimmune encephalomyelitis
(EAE) model in mice of some forms of multiple sclerosis (MS). Other studies
using knock-out (KO) mice have implicated nicotinic acetylcholine (ACh) receptors
containing α7, α9, or β2 subunits (α7∗-, α9∗- or β2∗-nAChR) in different, disease-
exacerbating or disease-ameliorating processes. These outcomes are in harmony
with gene expression analyses showing nAChR subunit mRNA in many classes of
immune system cell types. Consistent with influences on disease status, predictable
effects of nAChR subunit (and subtype) KO, or of nicotine exposure, are seen on
immune cell numbers and distribution and on cytokine levels or other markers of
immunity, inflammation, demyelination, and axonal degradation. Providing support
for our hypotheses about distinctive roles for nAChR subtypes in EAE, here we
have used direct and adoptive EAE induction and a nAChR subunit gene double
knock-out (DKO) strategy. Immune cell expression of nAChR α9 subunits as protein
is demonstrated by immunostaining of isolated CD4+, CD8+, CD11b+ and CD11c+
cells from wild-type (WT) mice, but not in cells from nAChR α9 subunit KO animals.
Nicotine exposure is protective against directly-induced EAE in WT or α7/α9 DKO
animals relative to effects seen in WT/vehicle-treated mice, but, remarkably, EAE
is exacerbated in vehicle-treated α7/α9 DKO mice. Brain lesion volume and intra-
cranial inflammatory activity similarly are higher in DKO/vehicle than in WT/vehicle-
treated animals, although nicotine’s protective effects are seen in each instance. By
contrast, in adoptive transfer studies, disease severity is attenuated and disease onset
Abbreviations: α7 or α9 KO, nicotinic acetylcholine receptor α7 or α9 subunit knock-out; ACh, acetylcholine; DKO,
double knock-out; EAE, experimental autoimmune encephalomyelitis; FACS, fluorescence-activated cell sorting; KO,
knock-out; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; MS, multiple sclerosis; nAChR,
nicotinic acetylcholine receptor(s); PBS, phosphate-buffered saline; ROS, reactive oxygen species; WT, wild-type.
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is delayed in recipients of splenocytes from WT animals treated with nicotine rather than
with vehicle. Moreover, protection as seen in nicotine-treated WT animals is the same
in recipients of splenocytes from nAChR α7/α9 DKO mice irrespective of their exposure
to nicotine or vehicle. When combined with previous observations, these findings are
consistent with disease exacerbation (or even induction) being mediated at least in part
via α9∗-nAChR in peripheral immune cells. They also suggest protective roles of central
nervous system (CNS) α7∗-nAChR. The results suggest that both α7∗- and α9∗-nAChR
are potential targets of therapeutic ligands to modulate inflammation and autoimmunity.
Keywords: auto-immunity, cholinergic anti-inflammatory pathway, experimental autoimmune encephalomyelitis,
inflammation, multiple sclerosis, nicotinic acetylcholine receptors
INTRODUCTION
It is widely recognized and undisputed that controlled
inflammatory and immune responses play critical roles in
maintenance of normal health by protecting against insults, in
part by clearing damaged cells, compromised tissue areas and/or
foreign substances (Weiner and Selkoe, 2002; Nikoopour et al.,
2008; Viganò et al., 2012). Conversely, aberrant or excessive
inflammatory or immune responses and anti-self, autoimmune
activities contribute to or literally cause a variety of diseases, such
as inflammatory bowel disease, arthritis and multiple sclerosis
(MS; Wekerle, 1998; Davidson and Diamond, 2001; Weiner
and Selkoe, 2002; Nikoopour et al., 2008; Franklin et al., 2012;
Pierson et al., 2012; Viganò et al., 2012; Lassmann, 2013; Laveti
et al., 2013). Our work reported here sought to illuminate new
bases for possible improvements in treatment of MS and other
diseases provoked by inflammation and hyper-immunity.
We and others have shown protection against inflammation
and immune hyper-responsiveness in the murine experimental
autoimmune encephalomyelitis (EAE) model of some forms of
MS upon sustained exposure to nicotine (Nizri et al., 2009; Shi
et al., 2009). These findings are consistent with other, prior work,
indicating that nicotine exposure inhibits, for example, T cell
differentiation (Sato et al., 1999; Matsunaga et al., 2001; Kuo
et al., 2002; Middlebrook et al., 2002; Kawashima et al., 2007;
Fujii et al., 2008), with long-recognized indications that nicotine
has anti-inflammatory and immunosuppressive effects (Ulloa,
2005; Cloëz-Tayarani and Changeux, 2007; Filippini et al., 2012),
and with the concept of a cholinergic anti-inflammatory system
(Tracey, 2009), which is postulated to suppress inflammatory and
immune responses by integrating signaling in the immune and
nervous systems.
Our subsequent studies have confirmed those protective
effects in the EAE model and have illuminated roles for different
nicotinic acetylcholine receptor (nAChR) subtypes in specific
features of the disease process or recovery and in protective
effects of nicotine exposure (Piao et al., 2009; Shi et al., 2009; Hao
et al., 2011, 2013; Simard et al., 2013). nAChR exist as pentamers
of nAChR subunits that are encoded from a mammalian family
of 16 different genes (Jensen et al., 2005; Lukas and Bencherif,
2006; Taly et al., 2009). nAChR thus also exist as a group of
subtypes, each defined by their distinctive subunit composition.
Subtypes have unique distributions across body organs, organ
(brain) regions, cell types and even across sub-cellular domains
(nerve cell soma, dendrites or axon terminals; pre-, post- or peri-
synaptic), and each nAChR subtype also has unique features
and characteristic responsiveness to acetylcholine (ACh) and
nicotine. nAChR nomenclature is based on subunit composition
to the extent that it is known or inferred, and an ‘‘∗’’ is used
to indicate a set of nAChR containing the specified subunits
but that additional and unspecified subunits may be or are
known to be partners in the receptor assembly (Lukas et al.,
1999).
Prior studies pointed to important roles for α7∗-nAChR
in the cholinergic anti-inflammatory pathway (Wang et al.,
2003; Shytle et al., 2004). Studies by us and others at first
seemed consistent with a dominant role for α7∗-nAChR in
protective effects of nicotine in EAE (Nizri et al., 2009; Hao
et al., 2011). In part, this is because the integrated disease
response, assessed based on signs of limb and tail weakness
in the EAE model, was attenuated by nicotine treatment in
wild-type (WT) animals, but not in nicotine-treated nAChR
α7 subunit knock-out (α7 KO) mice. Moreover, nicotine-treated
α7 KO mice did not differ in disease response from that
seen in α7 KO or WT mice exposed instead to vehicle (Hao
et al., 2011). The simplest interpretation was that elimination of
α7∗-nAChR seemed to eliminate nicotine protection. However,
the apparent absence of a difference in disease response in
vehicle-treated α7 KO compared to WT mice paradoxically
suggested that α7∗-nAChR did not mediate natural cholinergic
mechanisms involved in disease or in the response to disease
(Hao et al., 2011). In addition, deeper characterization involved
determinations of immune cell levels in the periphery and in
the central nervous system (CNS) and of levels of expression
of markers of inflammation and hyper-immunity. These levels
were not statistically different for vehicle-treated α7 KO or WT
animals, again suggesting lack of involvement of α7∗-nAChR
in natural, disease-related, cholinergic processes, which thus
must involve other nAChR subtypes. Nevertheless, inflammatory
and immune markers actually were suppressed in nicotine-
treated α7 KO animals, although not as much as by nicotine
exposure in WT mice (Hao et al., 2011). Among other things,
this suggested that nAChR subtypes in addition to α7∗-nAChR
also must be involved in nicotine’s protective effects (Hao et al.,
2011).
This intuition led to our finding that many immune
system cell types express a number of nAChR subunits,
most prominently α9 and β2 subunits (Hao et al., 2011),
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and that nicotine’s antagonism of α9∗-nAChR appears to be
responsible in large part for nicotine’s protective effects, which
are mimicked in nAChR α9 subunit KO mice (Simard et al.,
2013). This extended our knowledge about α9 subunits and
nAChR containing them, previously realized to be expressed
in the cochlea, olfactory epithelium and skin, but not in
the CNS (Jensen et al., 2005; Lukas and Bencherif, 2006;
Taly et al., 2009). Warranting emphasis, and possibly because
α9 subunits are the most ancient of known, mammalian
nAChR subunits, α9∗-nAChR have a unique and perhaps
similarly ancient pharmacological profile, in some ways akin
to GABA and glycine receptors, and respond to nicotine
as though it were an antagonist, rather than an agonist,
whereas nicotine is an agonist mimicking effects of ACh at
other nAChR subtypes. Thus, the finding is to be expected
that exposure to nicotine acting as an antagonist to block
α9∗-nAChR function, or elimination of α9∗-nAChR in a nAChR
α9 subunit KO (α9 KO) mouse, leads to the same level of
disease attenuation in the EAE model. In this case, elimination
of α9∗-nAChR eliminated nicotine protection, but this is
because nicotine effectively already produces elimination of
α9∗-nAChR. Importantly, the findings indicate that α9∗-nAChR
naturally contribute to disease-exacerbating effects (Simard et al.,
2013).
However, we require an improved understanding of
roles played by α9∗-nAChR in anti- or pro-inflammatory
responses, in disease-exacerbating or disease-attenuating
immune or immunosuppressive responses, and in effects
on those responses of nicotine exposure. Moreover, our
understanding is deficient about what immune or other
cell types express disease-relevant α9∗-nAChR. In addition,
the same questions can be raised about roles played by
α7∗-nAChR. For example, left open is the question about
if and how α7∗- and α9∗-nAChR interact in modulation
of inflammatory and immune processes. To address these
issues, we leveraged the availability of nAChR α7/α9 subunit
double knock-out (DKO) mice for study, also using direct and
adoptive transfer EAE models. The results confirm disease-
exacerbating roles for α9∗-nAChR, apparently restricted to
their expression in the periphery on immune system cells,




C57BL/6J mice used as WT controls sometimes were purchased
from Taconic Biosciences (Hudson, NY, USA), but they more
typically were WT littermates or colony controls generated
in the course of obtaining KO or DKO mice. Importantly,
no differences were observed in any experiments between
commercially-obtained C57BL/6 mice and the WT colony
controls or littermates of the extensively backcrossed DKO mice
used. The nAChR α9 subunit KO mouse model was generated
by the deletion of exons 1 and 2 and their flanking intronic
sequences (Genoway, Inc., Lyon, France). The embryonic stem
cells used to make the transgenic mouse line were from
the 129/svPas (129S2; 129/sv) strain. The α9 KO line was
backcrossed at the Boys Town National Research Hospital
(Omaha, NB, USA) to C57BL/6J mice (Jackson Laboratory,
Bar Harbor, ME, USA) using Marker-Assisted Accelerated
Backcrossing (MAX BAX; Charles River, Troy, NY, USA) until
congenicity (99+%) was achieved. Details about the development
of the α9 KO line have been described elsewhere (Morley
et al., 2017a,b). The animals are periodically backcrossed to
C57BL/6J mice to prevent genetic drift of the background
strain. The absence of α9 transcript and protein in cells
dissected from the retinas and inner ears of α9 KO mice has
been previously reported (Smith et al., 2014; Morley et al.,
2017b).
The nAChR α7 subunit KO strain was established from
mice obtained from the Jackson Laboratories (JAX; RRID:
IMSR_JAX:000664)1 as heterozygote breeders following
eight generations of backcrossing at JAX. The animals were then
further backcrossed for four generations at Boys Town National
Research Hospital using MAX BAX, and they have since been
periodically backcrossed with JAX C57BL/6J WT and nAChR
α7 subunit KO animals to prevent genetic drift.
The α7/α9 DKO strain was established by breeding nAChR
α9 subunit KO heterozygote females with nAChR α7 subunit KO
males. Subsequent crossings used α7 or α9 female heterozygotes
or α9 KO females mated with α7 or α9 male heterozygotes or KO
animals.
For the studies reported here, mice were bred and housed
at Boys Town National Research Hospital until maturity and
shipped by overnight courier to the Barrow Neurological
Institute (Phoenix, AZ, USA). The animals were bred under
presumed identical conditions and tested negative for all
standard viruses and parasites by IDEXX (Columbia, MO, USA).
The litter sizes for all strains varied from 5 to 9. Dams and
males in our colony are typically first bred at 6–8 weeks of age,
not utilized for more than two litters, and are rarely bred past the
age of 12–14 weeks. Young dams andmales are used for breeding
to reduce the incidence of epigenetic factors that might affect the
phenotype.
All animal studies were approved by Animal Care and Use
Committees of the Barrow Neurological Institute or Boys Town
National Research Hospital.
Immunostaining
T (CD4+ or CD8+), monocyte/macrophage (CD11b+) or
dendritic (CD11c+) cells from the spleens of WT or DKO
mice were isolated using fluorescence-activated cell sorting
(FACS) as described previously (Li et al., 2017). For FACS
analysis, single cell suspensions (106 cells) of splenocytes were
stained with fluorochrome-conjugated antibodies. Targets and
antibodies used (BD Biosciences, Franklin Lakes, NJ, USA)
were: CD3 (145-2C11), CD4 (GK1.4), CD8 (53–6.7), CD11b
(M1/70), CD11c (HL3). Flow cytometric data were collected
on a FACSAria flow cytometer (BD Biosciences) and analyzed
with Diva software. Isotype-matched negative control mAbs
1https://www.jax.org
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 September 2017 | Volume 11 | Article 287
Liu et al. Distinctive Nicotinic Modulation of Inflammatory Processes
were used for all stains. Sorted cells were collected in conical
tubes and then seeded on cover slips. For immunostaining,
FACS-sorted cells were fixed in 4% paraformaldehyde for
10 min and washed at room temperature with phosphate-
buffered saline (PBS) three times for 5 min each. A PBS-based
solution containing 5% blocking serum and 0.3% Triton X-100
was applied for 1 h. Cells were incubated at 4◦C overnight
with primary antibodies and for 1 h at room temperature with
Alexa Fluor–conjugated secondary antibodies. Cells were then
washed three times for 5 min each with PBS and prepared
for fluorescence microscopy as previously described (Liu et al.,
2009, 2013). The following primary antibodies were used: goat
anti-nAChR α9 antibody (E-17, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-CD4 antibody (H-370,
Santa Cruz Biotechnology), rat anti-CD8 antibody (2.43, Santa
Cruz Biotechnology), rabbit anti-CD11b antibody (Abcam, San
Francisco, CA, USA) and rabbit anti-CD11c antibody (EP1347Y,
Abcam).
EAE Induction
The mouse peptide MOG35–55 (myelin oliogodendrocyte
glycoprotein; amino acids MEVGWYRSPFSRVVHLYRNGK)
was synthesized (purity>95%) by Bio-Synthesis, Inc. (Lewisville,
TX, USA). To induce EAE directly, mice were injected
sub-cutaneously in the hind flank with 200 µg MOG35–55
peptide in complete Freund’s adjuvant (BD Biosciences)
containing 500 µg of nonviable desiccated Mycobacterium
tuberculosis. On the day of immunization and 2 days after,
mice also were injected intravenously with 200 ng pertussis
toxin (List Biological Laboratories, Campbell, CA, USA).
Passive induction (adoptive transfer) EAE was initiated by
transfers of splenocytes isolated from donor mice in which
a direct EAE response was initiated as previously described
(Huang et al., 2006; Hao et al., 2010). In brief, splenocytes
were obtained from either WT or α7/α9 DKO donor mice,
treated with either PBS vehicle or with nicotine starting on
the day of immunization, 14 days after immunization with
MOG35–55. Thereafter, splenocytes were cultured in the presence
of 30µg/mlMOG35–55 and 20 ng/ml recombinant interleukin-12
(R&D Systems). After culture for 3 days, cells were collected
and washed in PBS. 1 × 107 splenocytes were transferred into
Rag2−/− mice by intravenous injection. Recipient mice also
were given 200 ng pertussis toxin intravenously on the day
of cell transfer and 2 days after transfer. Whether for direct
or adoptively transferred EAE, mice or recipient mice were
monitored daily for symptoms scored on an arbitrary scale of
0–5 as previously described (Hao et al., 2011; Simard et al.,
2013).
Histological Analyses
At specific times after direct or adoptively transferred EAE
induction, mice displaying disease scores typical of their group
were anesthetized by 2% isoflurane inhalation and perfused
by intracardiac puncture with 50 ml of cold PBS. Spinal
cords were removed and fixed in 10% formalin/PBS. Paraffin-
embedded, longitudinal sections running across the cervical
enlargement were prepared and stained for infiltrating immune
cells (hematoxylin and eosin), myelin (luxol fast blue) and
axons (Biechowsky silver). Manual tracing was used to define
the degree of inflammation, demyelination, and axonal damage
across the entire spinal cord section for each mouse. Evidence
of pathology was scored as follows: 0, no changes; 1, focal
area involvement; 2, <5% of total myelin area involved; 3,
5%–10% of total myelin area involved; 4, 10%–20% involved
area; 5, >20% of total myelin area involved (Bai et al.,
2004).
Nicotine Treatment
(−)Nicotine bitartrate was purchased from Sigma (St. Louis,
MO, USA). A 100 mg/ml solution of nicotine salt in PBS,
or a solution containing PBS alone, were freshly prepared
and loaded into Alzetr osmotic minipumps (model 1004,
Durect Corporation, Cupertino, CA, USA) 24 h before pump
implantation as described (Simard et al., 2013). On the
day of MOG immunization, the minipumps were implanted
subcutaneously on the right side of the back of the mouse and
continuously delivered either PBS or nicotine salt at 12 µl/d
until the end of experiments. This dosing regimen is designed
to produce plasma levels of nicotine in the relevant animals of
∼49 ng/ml or ∼300 nM, which is comparable to concentrations
of nicotine typically found in human cigarette smokers and is
behaviorally relevant in mice (Matta et al., 2007).
7T Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed using a
7 Tesla, small animal, 30 cm horizontal-bore magnet and
BioSpec Avance III spectrometer (Bruker Biospin MRI, Billerica,
MA, USA) as previously described (Hao et al., 2010; Liu
et al., 2017) Mice were under anesthesia by inhalation of
3.5% isoflurane and maintained by inhalation of 1%–2%
isoflurane in 70% N2O and 30% O2 delivered via a face
mask. During MRI scans, animal respiration was continually
assessed by a small animal monitoring and gating system
(SA Instruments, Stony Brook, NY, USA) via a pillow
sensor positioned under the abdomen. Axial 2D multi-
slice T2-weighted images of the brain were acquired with
fat-suppressed Rapid Acquisition with Relaxation Enhancement
sequence (TR = 4000 ms, effective TE = 60 ms, number of
average = 4, FOV = 19.2 mm × 19.2 mm, matrix size = 192 mm
× 192 mm, slice thickness = 0.5 mm, TA = 6 m 24 s).
MRI data were analyzed using the MEDx3.4.3 software package
(Medical Numerics, Germantown, MD, USA) on a LINUX
workstation.
In Vivo CNS Bioluminescence
To assess reactive oxygen species (ROS) production in brain,
bioluminescence images were captured in live mice using a
Xenogen IVIS200 imager (Caliper Life Sciences, Hopkinton,MA,
USA) 20 min after i.p. injection of 100 µl of 50 mg/ml Luminol
(Sigma-Aldrich, St. Louis, MO, USA) as we previously described
(Hao et al., 2010; Simard et al., 2013). Regions of interest were
selected to measure luminescence intensity in the brain. Data
were collected as photons/sec/cm2 using Living Imager software
(Caliper Life Sciences, Hopkinton, MA, USA).
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Statistical Analyses
Data are presented as Mean± SEM. Differences were considered
significant at p< 0.05. Statistical differences among groups were
evaluated by two-tailed unpaired Student’s t-test for two groups
and by one-way analysis of variance (ANOVA) followed by
Tukey post hoc test for three or more groups. Two-way ANOVA
accompanied by a Bonferroni post hoc test was used for multiple
comparisons. All statistical analyses were performed using Prism
5.0 software (GraphPad, San Diego, CA, USA).
RESULTS
Expression Profile of nAChR α9 Subunit in
Immune Cells
To validate the expression of the nAChR α9 subunit gene
as protein in selected immune cell types, we subjected T
(CD4+ or CD8+), monocyte/macrophage (CD11b+) or dendritic
(CD11c+) cells, isolated by FACS from the spleens of WT
mice, to immunostaining with cell-specific markers and with an
antibody against α9 subunits. All of these immune cell types
display nAChR α9 subunit-like immunoreactivity (Figure 1).
However, similar assessment in immune cells from nAChR
α9 subunit KOmice were negative for subunit immunoreactivity
(results for CD4+ T cells are shown; Figure 1). Interestingly,
CD4+ T cells from nAChR α9 subunit KO mice are smaller than
those fromWTmice, likely indicative of immaturity.
Nicotine Treatment Attenuates Direct EAE
Severity in Both WT and α7/α9 DKO Mice,
but in the Absence of Nicotine Treatment,
There Is Exacerbation of Direct EAE
Severity in DKO Compared to WT Animals
Our previous studies initially indicated equivalence, in disease
scores and other indications of immunity and inflammation,
between WT animals continuously exposed to nicotine and
nAChR α9 subunit KO animals irrespective of whether they
were exposed to nicotine or vehicle. Each of these three
cohorts of animals had reduced severity or other indices of
disease compared to vehicle-treated WT animals (Simard et al.,
2013). Our initial studies using nAChR α7 subunit KO animals
suggested that they did not differ from WT animals in disease
score measures when treated with vehicle alone, or when α7 KO
mice were exposed to nicotine, which was protective against
disease in WT animals (Hao et al., 2011). Other markers of
immunity and inflammation in vehicle-treated α7 subunit KO
animals or WT mice were indistinguishable. However, nicotine
exposure did produce attenuation of indices of immunity and
inflammation in α7 KO animals, although not at the higher
levels of attenuation seen in nicotine-treated WT mice. These
findings suggested involvement of other nAChR subtypes in
disease and protection against it. Although recognizing that there
might be potential challenges in data interpretation in such
studies, we nevertheless sought to determine effects on disease
and nicotine protection in animals lacking both nAChR α7 and
α9 subunits.
Comparable degrees of protection against disease in
the direct EAE model again are seen in WT animals and
in α7/α9 DKO mice continuously exposed to nicotine
(Figure 2; Table 1). These effects also are equivalent to
those seen upon deletion only of α9 subunits (Simard
et al., 2013). Treatment with the ligand delays the onset
(by 2 days in this cohort) and attenuates the severity of
disease response (by ∼25%–33%) relative to the disease
course in control, vehicle-treated WT animals (peak clinical
scores: 2.8 ± 0.2 WT/vehicle vs. 1.9 ± 0.1 WT/nicotine,
p < 0.01; vs. 2.1 ± 0.1 α7/α9 DKO/nicotine, p < 0.01;
Figure 2; Table 1). However, and remarkably, direct
EAE severity is elevated (by ∼36%) in α7/α9 DKO mice
exposed only to vehicle relative to effects in WT control
animals (peak clinical scores: 2.8 ± 0.8, WT/vehicle vs.
3.8 ± 0.8 α7/α9 DKO/vehicle, p < 0.01; Figure 2; Table 1;
Disease severity: α7/α9 DKO:saline > WT:saline > α7/α9
DKO:nicotine = WT:nicotine). Differences between groups in
peak disease severity are preserved over the ∼2 weeks when
recovery occurs in these animals.
FIGURE 1 | Expression of nicotinic acetylcholine receptor (nAChR) α9 subunit protein in immune cells. Immunostaining for nAChR α9 subunit protein (green) was
done for the indicated, peripheral T (CD4+ or CD8+), monocyte/macrophage (CD11b+) or dendritic (CD11c+) cells labeled with cell surface marker-specific
antibodies (red), and counterstained with nuclear DAPI (blue), from a wild-type (WT) mouse, or for a representative CD4+ T cell from a nAChR α7/α9 subunit double
knock-out (DKO) animal (α7−/−α9−/−). Note that all immune cell types from the WT mouse demonstrate α9 subunit-like immunoreactivity, but that absence of
immunoreactivity in the T cell from the DKO animal confirms elimination of α9 subunits, also validating specificity of the commercial antibody used. Scale bar: 5 µm.
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Brain Lesion Volume Is Larger, and Levels
of Reactive Oxygen Species Are Elevated,
at Peak, Directly-Induced EAE, in
α7/α9 DKO Mice Compared to Results
using WT Animals, but Nicotine Treatment
Lessens Lesion Volume and Inflammation
in Both α7/α9 DKO and WT Mice
Consistent with disease scores, MRI assessments of brain
lesion volume at disease peak are reduced (∼18%–27%) in
nicotine-treated, WT or α7/α9 subunit DKO mice relative to
effects seen in WT animals treated with vehicle (Figure 3).
Lesion volumes are 5.2 ± 0.5 mm2 for WT/vehicle mice
vs. 3.8 ± 0.3 mm2 for WT/nicotine animals (p < 0.01) and
4.3 ± 0.5 mm2 for α7/α9 DKO/nicotine mice (p < 0.01).
However, compared to results in vehicle-treated WT mice,
lesion volumes are elevated by about 37% in vehicle-
treated α7/α9 DKO mice (7.1 ± 1.1 mm2), also consistent
with the higher disease scores in these animals (Brain
lesion volume: α7/α9 DKO:saline > WT:saline > α7/α9
DKO:nicotine = WT:nicotine).
Similarly, bioluminescence measurements [quantified
in (photons/sec/cm2)/105] of brain inflammation at peak
disease based on ROS visualization are ∼16%–26% lower,
when compared to those in vehicle-treated WT animals
(4.3 ± 0.3), in both nicotine-treated WT mice (3.2 ± 0.3)
or nicotine-treated α7/α9 DKO animals (3.6 ± 0.4;
p < 0.01 for both; Figure 4). Nevertheless, there is significantly
elevated (∼21%) CNS ROS production in vehicle-treated
α7/α9 DKO (5.2 ± 0.5; p < 0.01 to each of the other
groups (Figure 4), again reflecting higher disease scores
(and brain lesion volume) in the latter group (Figure 4;
Brain inflammation: α7/α9 DKO:saline > WT:saline > α7/α9
DKO:nicotine = WT:nicotine).
FIGURE 2 | Exacerbated, direct experimental autoimmune encephalomyelitis
(EAE) severity in α7−/−α9−/− mice. EAE disease symptom evaluation was
done for groups of WT or nAChR α7/α9 subunit DKO (α7−/−α9−/−) mice
receiving phosphate-buffered saline (PBS) or nicotine treatment. PBS or
nicotine was delivered via minipumps until the end of experiment. The
minipumps were implanted subcutaneously and continuously delivered either
PBS or nicotine salt at an equivalent of ∼13 mg of nicotine free base/kg/day.
In the absence of nicotine treatment, exacerbated EAE severity was seen in
α7−/−α9−/− mice (α7−/−α9−/− + PBS; N; n = 8) vs. WT controls (WT + PBS;
•; n = 7). Nicotine treatment reduced EAE severity in both α7−/−/α9−/−
(α7−/−/α9−/− + nicotine; ; n = 7) and WT mice (WT + nicotine; ; n = 7).
Mean ± SEM; two-way analysis of variance (ANOVA); ∗∗p < 0.01.
Protection Against Adoptively Transferred
EAE Induced by Nicotine Exposure or by
Deletion of Both nAChR α7 and
α9 Subunits in Donors
α7∗-nAChR are widely dispersed in central and autonomic
nervous systems and are present in immune cell types.
TABLE 1 | Summary of EAE studies across nAChR subunit genotypes and treatments.
Animal (genetic status) Treatment Direct EAE severity
(+, ++, +++ scale)
Reference(s) Adoptive transfer EAE severity
(genetic status and treatment
of donor; wild-type recipient;
+, ++, +++ scale)
Reference(s)
Wild-type Saline ++ Shi et al. (2009); Hao et al.
(2011); Simard et al. (2013)
++ Shi et al. (2009)
This report Figure 3
Nicotine + This report Figure 1 +
α7 KO Saline ++ Hao et al. (2011)
Nicotine ++
α9 KO Saline + Simard et al. (2013)
Nicotine +
α7/α9 DKO Saline +++ This report Figure 1 + This report Figure 3
Nicotine + +
Direct or adoptive EAE severity scores (scale of + to +++) are illustrated for animals with the indicated genotype and treatments (nicotine to yield blood levels of ∼300 nM
or saline alone) following experimental procedures as described in the “Materials and Methods” Section of this report or in the cited publication(s). Disease severity in
direct EAE (++ level) is like that in wild-type (WT) animals treated with saline or in nAChR α7 subunit knock-out (α7 KO) animals irrespective of nicotine or saline treatment
(WT:saline = α7 KO:saline = α7 KO:nicotine) and also is at positive control levels of disease in recipients of adoptively transferred splenocytes from WT animals treated
with saline. Direct EAE disease severity is attenuated to essentially equivalent degrees in WT, α9 KO, or α7/α9 double knock-out (DKO) animals treated with nicotine, or
in α9 KO animals treated with saline (WT:nicotine = α9 KO:nicotine = α7/α9 DKO:nicotine = α9 KO:saline), and there is similar attenuation of adoptively transferred EAE
disease severity upon nicotine treatment of WT or α7/α9 DKO donor animals or for saline-treated α7/α9 DKO mice. Remarkably, direct EAE disease severity is worst for
saline-treated α7/α9 DKO mice.
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FIGURE 3 | Increased brain lesion size in α7−/−/α9−/− mice during the peak phase of direct EAE. (A) T1-weighted images were obtained with a 7T magnetic
resonance imaging (MRI) scanner in WT or nAChR α7/α9 subunit DKO (α7−/−/α9−/−) mice receiving PBS or nicotine treatment. Mice received i.v. injections of
gadolinium prior to MRI scans. Arrows indicate focal lesions in the brain and increased signal intensity on T1-weighted images. MRI scans were conducted in groups
of mice (n = 5) at day 14 after immunization. PBS or nicotine was delivered via minipumps until the end of experiment. The minipumps were implanted
subcutaneously and continuously delivered either PBS or nicotine salt at an equivalent of ∼13 mg of nicotine free base/kg/day. (B) Bar graph shows quantified data.
Mean ± SEM; one-way ANOVA; ∗p < 0.05, ∗∗p < 0.01.
α9∗-nAChR appear to be absent in the CNS but are present
much more abundantly than α7∗-nAChR in immune system
cells (see ‘‘Discussion’’ Section). To determine effects of selective
elimination of both subunits from immune system cells capable
alone of conferring EAE to recipient mice, we also established
effects of nAChR α7/α9 DKO in the adoptive transfer model
of EAE. WT or DKO donor mice were treated with vehicle
alone or supplemented with nicotine and inoculated with
MOG peptide. Total splenocytes taken from animals at peak
disease were isolated and transferred in Rag2−/− recipients
having the full contingent of nAChR subunits but lacking
T, natural killer T, and B cells. Rag2−/− recipients receiving
splenocytes from vehicle-treated WT animals develop severe
EAE (peak clinical score 3.5 ± 0.2; Figure 5; Table 1).
However, EAE disease symptoms are attenuated (∼30%)
and delayed (∼2–3 days) in recipients of splenocytes from
nicotine-treated WT mice (2.2 ± 0.1) or from nicotine-
treated DKO animals (2.4 ± 0.2; p < 0.01 for both;
Figure 5; Table 1). A comparable degree of protection against
adoptively transferred EAE is also seen for Rag2−/− mice
receiving splenocytes from DKO animals treated with vehicle
alone (peak clinical score of 2.6 ± 0.2; p < 0.01 relative
to WT/vehicle control; Figure 5; Table 1; Disease severity:
WT:saline > α7/α9 DKO:saline = α7/α9 DKO:nicotine = WT:
nicotine).
DISCUSSION
Immunostaining with a Validated Antibody
Confirms nAChR α9 Subunit Expression as
Protein in Immune System Cells, and T Cell
Maturation Appears to be Inhibited in
nAChR α9 Subunit KO Mice
Results in this study indicate that many immune cell types
express nAChR α9 subunits not only as mRNA, as previously
shown (Hao et al., 2011), but also as protein, identified by
immunostaining of peripheral (splenic) CD4+ and CD8+ T
cells, CD11b+ monocytes/macrophages, and CD11c+ dendritic
cells. This is consistent with other results demonstrating
function of peripheral immune cell α9∗-nAChR in disease
model studies based on gene deletion or nicotine antagonism
(Simard et al., 2013). The finding that immunostaining is
absent in nAChR α7/α9 DKO mice lacking α9 subunits
supports specificity of the anti-α9 subunit antibody used,
which is important to demonstrate for anti-nAChR subunits
(Jones and Wonnacott, 2005; Moser et al., 2007). Reciprocally,
that observation also demonstrates that genetic elimination
of α9 subunits translates into an absence of subunit protein.
The finding that CD4+ T cell size is smaller in α9 KO
animals is consistent with earlier studies showing that nicotine
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FIGURE 4 | Enhanced brain inflammation on α7−/−α9−/− mice during the
peak phase of direct EAE. (A) Visualization and quantification of brain
inflammation by in vivo bioluminescence imaging was conducted in WT or
nAChR α7/α9 subunit DKO (α7−/−/α9−/−) mice receiving PBS or nicotine
treatment. Images were captured using a Xenogen IVIS200 imager. Data were
collected as photons per second per centimeter squared using Living Image
software (Caliper Life Sciences). Images were obtained from groups of mice
(n = 6) at day 14 after immunization. PBS or nicotine was delivered via
mini-pumps until the end of experiment. The pumps were implanted
subcutaneously and continuously delivered either PBS or nicotine salt at an
equivalent of ∼13 mg of nicotine free base/kg/day. (B) Bar graph shows
quantified data. Mean ± SEM; one-way ANOVA; ∗p < 0.05, ∗∗p < 0.01.
exposure, which antagonizes α9∗-nAChR function, inhibits T
cell differentiation and maturation, manifest as smaller size of
those cells produced in thymic organ cultures and when assessed
using flow cytometry (Middlebrook et al., 2000, 2002). The
observation that elimination of nAChR α9 subunits (and α9∗-
nAChR) has anti-inflammatory and immunosuppressive effects
is consistent with evident immaturity or anergy of T cells in
α9 KO animals.
α9∗-nAChR Roles in Disease Exacerbating
Effects
In the direct EAE model, nicotine exposure is confirmed
again to delay the onset and to attenuate the severity of
EAE in WT mice, and effects are shown here for the
first time to be similar in nicotine-treated α7/α9 DKO
animals. Brain lesion volumes and levels of ROS markers of
inflammation are comparably lowered in nicotine-treated WT
or α7/α9 DKO mice, paralleling as expected effects on the
integrated response measured by disease score. This all is
consistent with the equivalence of nicotine’s protective effects
in WT or α9 KO mice, mimicking effects in vehicle-treated
α9 KO mice; nicotine’s protective effects wouldn’t be expected
to add to already protective effects of nAChR α9 subunit
FIGURE 5 | Reduced severity upon adoptive transfer EAE in Rag2−/− mice
receiving splenocytes from α7−/−α9−/− mice. EAE disease symptom
evaluation was done for Rag2−/− mice receiving splenocytes on Day 0 from
either WT or nAChR α7/α9 subunit DKO (α7−/−α9−/−) mice 14 days after the
donors were immunized with MOG35–55. Donors also were treated starting on
Day 0 with either PBS or nicotine delivered via minipumps until donation. In
the absence of nicotine treatment, EAE was conferred by transfer of
splenocytes from WT mice into Rag2−/− recipients (WT + PBS; •), implicating
immune cells originating in the periphery in the disease process (∗∗denotes
p < 0.01 for difference in disease score vs. the other groups). Delayed onset
and lessened severity of disease signs were observed in animals receiving
splenocytes from nicotine-treated DKO (α7−/−α9−/− + nicotine; ) or WT
mice (WT + nicotine; ). Note that there is protection at the same level when
splenocytes from DKO mice treated just with vehicle were transferred into
Rag2−/− recipients (α7−/−α9−/− + PBS; N), implicating peripheral immune
cells expressing α9∗-nAChR and a requirement for functional α9∗-nAChR
expression in disease-exacerbating inflammatory and autoimmune effects.
Nicotine’s effects could be due to blockade of functional α9∗-nAChR on
peripheral immune cells. n = 8. Mean ± SEM; two-way ANOVA; ∗∗p < 0.01.
deletion in α9 KO mice (as seen in Simard et al., 2013). The
interpretation of this collective body of evidence is that α9∗-
nAChR play roles in initiation or exacerbation of disease-relevant
inflammatory and immune responses. Their antagonism by
nicotine or their elimination in α9 KO mice lessens disease
burden and disease-exacerbating inflammatory and immune
responses.
Multiple Targets and Disease Thresholds
for Nicotine’s Protective Effects
In the directly-induced EAE model, protective effects of nicotine
exposure in WT and in α7/α9 DKO mice contrast with the
initially-apparent loss of nicotine’s protective effects, at least in
terms of the integrated EAE disease response, in nAChR α7 KO
mice (Hao et al., 2011). Why would sustained nicotine exposure
not appear to be protective in α7 KO mice but protective in
α7/α9 DKO mice, where its antagonism of α9∗-nAChR would
be expected to be redundant with α9∗-nAChR elimination?
One possibility is that the integrated disease response emerges
once a threshold of inflammatory activity and hyper-immunity
is achieved. That would imply that nicotine treatment in
α7 KO mice inadequately suppresses such activity to below
threshold levels. This is consistent with observations that nicotine
treatment does diminish other indices of inflammation and
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immunity in α7 KO mice, but just not to the same degree
as nicotine attenuates such responses in WT animals (Hao
et al., 2011). A related interpretation is that α7∗-nAChR play
protective roles, and that their elimination in α7 KO animals
lowers the threshold for development of disease to a level that
is not overcome by nicotine exposure. Our previous studies have
shown that expression levels of cytokines or other inflammatory
factors change predictably in reflection of disease severity, but
inflammatory status of α7/α9 DKO mice during EAE warrants
further investigation, as we plan. Regardless, it is evident from
nicotine’s protective roles in α7/α9 DKO mice that nicotine
has additional targets other than α9∗- and α7∗-nAChR that are
relevant to the EAE inflammatory and immune process (Simard
et al., 2013).
Newly Revealed, Natural Protective Effects
of α7∗-nAChR
Another important observation is that directly-induced EAE
severity is elevated in vehicle-treated α7/α9 DKO mice
compared to vehicle-treated WT animals. This contrasts with
the aforementioned protective effects of α9 KO alone and with
the initially-apparent null effect of α7 KO alone when disease
manifestation is considered in comparison to that in vehicle-
treated WT animals. Viewed one way, our interpretation is
that there is a loss of protection against direct EAE due to
elimination of naturally-functioning α7∗-nAChR, even when
α9∗-nAChR also are deleted. Phrased differently, we postulate
that upon elimination of disease-exacerbation attributable to
α9∗-nAChR expression, additional elimination of α7 subunits
reveals protective effects of α7∗-nAChR responding to natural
chemical signals.
Importance in Disease Exacerbation of
Peripheral Immune Cell α9∗-nAChR, and
Support for Protective Roles of α7∗-nAChR
in the CNS
The interpretations and hypotheses advanced here thus far were
tested in adoptive transfer EAE studies. Our previous work
showed that nicotine treatment is comparably if not more
potent in attenuating disease signs in the passive EAE model
employing transfer of immune system cells from inoculated,
nicotine- or vehicle-treated, WT donors to otherwise naïve,
Rag2−/− recipients when compared to nicotine’s protective
effects against direct EAE (Shi et al., 2009). Here we show
that nicotine exposure in inoculated, WT or α7/α9 DKO
animals indeed protects against diseasemanifestation in Rag2−/−
recipients of immune cells from those donors compared to
effects seen for transfer of immune cells from vehicle-treated
WT animals. Moreover, adoptive transfer of cells from vehicle-
treated α7/α9 DKO animals similarly produces attenuated
disease in recipients. Our interpretation of these observations
is that nicotine antagonism of α9∗-nAChR, or genetic deletion
of α9∗-nAChR, has protective effects because they block or
eliminate functional α9∗-nAChR in peripheral immune cells.
This finding makes sense given the known disposition of α9∗-
nAChR (Elgoyhen et al., 1994; Jensen et al., 2005). It is reported
that nAChR α9-like immunoreactivity seems to be present in the
healthy piglet or infant mouse brain (Vivekanandarajah et al.,
2015, 2016). However, previous in situ hybridization or other
measures of transcript levels (e.g., see Elgoyhen et al., 1994;
Hao et al., 2011), validated by recent RefSeq data2, indicate
that healthy mouse brain expression of nAChR α9 subunit
mRNA is vanishingly low (below or at detection levels), in
contrast to robust thymic (e.g., 11.423 RPKM) or immune cell
levels. Furthermore, our own observations (in preparation) are
entirely consistent with RefSeq3 data indicating that healthy
human CNS levels of nAChR α9 subunits also are vanishingly
low (0.154 ± 0.104 RPKM), whereas immune cell levels are
substantial. Further work will ascertain whether these situations
are different in diseased brain or immune system cells, across
species, or across different techniques for assessment of subunit
protein or message levels.
In addition, these findings indicate that elimination of
nAChR α9 subunits in immune cells is protective even in the
absence of immune cell α7 subunits and α7∗-nAChR. Moreover,
the fact that adoptively-transferred disease is attenuated in
the passive EAE model rather than exacerbated, as seen
in the direct EAE model, in vehicle-treated α7/α9 DKO
mice, indicates that elimination of α7∗-nAChR in peripheral
immune cells is not damaging. This finding also supports the
hypothesis/interpretation that protective roles for α7∗-nAChR
revealed in direct EAE studies using α7/α9 DKO mice are due
to actions of those α7∗-nAChR in the CNS.
Past, Present and Future Perspectives
Delicate balancing of pro- vs. anti-inflammatory responses, and
between activation or suppression of immune responses, requires
cross-talk between the immune and nervous systems. Such cross-
talk, and neuroimmune sharing of signaling molecules and
mechanisms, even contributes to nervous system development
and plasticity (Boulanger, 2009; Shatz, 2009; Besedovsky and del
Rey, 2011). The chemical signaling agent, ACh, now is realized
not just to have specialized activity as a neurotransmitter in
the nervous system, but also to have actions in non-neuronal
tissues and organs, such as in the immune system (Grando
et al., 2012). There is no doubt that chemical sensing existed
long before the emergence of nervous systems and concurrent
specialization of chemical messengers and their targets to execute
synaptic neurotransmission (Wessler and Kirkpatrick, 2008).
ACh is among the primordial chemical messengers involved in
chemical sensing long before they acquired more specialized
functions as synaptic vesicle-packaged neurotransmitters. Even
in advanced organisms with robust nervous systems, there now
is solid evidence for cholinergic signaling and for the existence of
enzymes that synthesize and degrade ACh in other organs and
cell types, including in the immune system (Sato et al., 1999;
Matsunaga et al., 2001; Kuo et al., 2002; Middlebrook et al.,
2002; Kawashima et al., 2007; Fujii et al., 2008; Koval et al.,
2011). Implications are that locally-synthesized and released ACh
plays paracrine- or autocrine-type roles in these organs, but
2https://www.ncbi.nlm.nih.gov/gene/231252
3https://www.ncbi.nlm.nih.gov/gene/55584
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not discounted are possible origins of ACh from terminals of
neurons providing fine innervation of those organs. However,
our understanding is immature about how this ‘‘non-neuronal’’
cholinergic signaling is leveraged and the depth and breadth
of its involvement in control of extra-neuronal cell and organ
function.
α7∗-nAChR were the first suggested to be involved in the
so-called ‘‘cholinergic anti-inflammatory pathway’’ (Wang et al.,
2003; Shytle et al., 2004). That implication now indeed seems
validated, despite the initially-observed null effect of α7 KO on
direct EAE disease signs (Nizri et al., 2009; Hao et al., 2011) which
suggested that α7-nAChRs are not key players in endogenous,
nAChR-dependent, immunoregulatory processes in that model.
Instead, the exacerbation of direct EAE disease in α7/α9 DKO
mice reveals protective roles of α7∗-nAChR responding to
natural cholinergic signals. This also is consistent with deeper
analysis of the results using α7 KO animals showing some, but
only partial, attenuation of other inflammatory and immune
response indices in the presence of nicotine as opposed to vehicle,
thus revealing that α7∗-nAChR mediate some but not all of the
effects of nicotine treatment, as one might expect for nAChR
also mediating natural cholinergic signals (Hao et al., 2011).
However, such roles do not seem to be due to α7∗-nAChR in
peripheral immune cells, based on adoptive transfer studies using
α7/α9 DKO mice. Nevertheless, nicotine protection remains
evident in direct EAE studies using α7/α9 DKO mice, suggesting
that additional nAChR subtypes are involved, not only in its
effects, but also in natural cholinergic mechanisms.
In interpretation of effects of sustained nicotine exposure,
there needs to be cognizance of how those effects can deviate
substantially from those of acute exposure to nicotine (Lukas,
1991, 1995, 1998; Lukas et al., 1996; Gentry and Lukas, 2002;
Gentry et al., 2003). Acute exposure to nicotine or ACh
stimulates nAChR channel opening (as noted above, except
for α9∗-nAChR, where nicotine is an antagonist rather than
an agonist like ACh), but this effect is only transient. More
sustained exposure can lead to functional ‘‘desensitization, ’’ and
then to progressively ‘‘deeper’’ levels of ‘‘functional’’/‘‘persistent’’
inactivation (Lukas et al., 1996; Gentry and Lukas, 2002).
These longer-term effects, just as for acute actions of ligands,
differ across nAChR subtypes with regard to potency, and they
likely reflect a mixture of receptor activation and inactivation
(Picciotto et al., 2008). It remains controversial whether nAChR
subtypes, such as α7∗-nAChR, would be affected at all by
nicotine at concentrations achieved via minipump delivery as
used in the current studies. It also is not entirely clear whether
nicotine exposure as produced in our studies would promote low
level activation of specific nAChR subtypes or their functional
inactivation. It also is possible that nAChR channel function
is not relevant in the immune cell context, where nAChR
occupancy might be adequate to alter intracellular signaling.
Even for α9∗-nAChR, it is not clear that nicotine exposure
as in these studies would be sufficient to antagonize channel
function, especially if overcome by natural cholinergic signals.
Also to be defined is where and how immune cells are exposed
to natural cholinergic signals. Thus, much more work is required
to define mechanisms involved in the clear and indisputable
protection against disease in the EAE model mediated by
nicotine.
Evidence continues to build that phylogenetically-ancient
α9∗-nAChR naturally play disease-exacerbating roles coincident
with elevated immunity and inflammation. This challenges
the notion of the cholinergic anti-inflammatory system,
because α9∗-nAChR function seems to be anything but anti-
inflammatory. Indeed, roles of α9∗-nAChR in endogenous
pro-inflammatory mechanisms contributing to disease initiation
and evolution are likely triggered by the endogenous agonist,
ACh. Yet to be tested are hypotheses that function of α9∗-
nAChR is required or important for maturation of T cells and
perhaps other immune cell types. A consequence of nicotine
antagonism-mediated α9∗-nAChR functional blockade or of
α9 KO producing elimination of functional α9∗-nAChR, either
leading to immune cell quiescence, could account for the
attenuated disease response and suppression of immunity and
inflammation.
As to be expected, our findings in the current study pose
new questions that await future investigation. First, it remains
to be determined whether deletion of specific nAChR subunits
leads to compensatory changes in others, although RT-PCR
studies do not indicate dramatic changes in levels of other
nAChR subunit messages in α7 KO mouse immune cells, brain,
or brain microglia (Hao et al., 2011). Second, there could be
influences of disease state on nAChR subtype and subunit
expression, also as suggested by our earlier work (Hao et al.,
2011). Third, expression of nAChR that mediate natural effects
of ACh and/or summed protective effects of nicotine in different
immune cell types is incompletely understood. For example, it
is reported that nAChR α7 and α9 subunits are expressed by
CD4+ and CD8+ T cells (Qian et al., 2011), consistent with
our observations (Hao et al., 2011). Moreover, regulatory T
cell responses appear to be dependent on α7-nAChR (Wang
et al., 2010). Infiltrating macrophages or microglia in the brain
are also key players in EAE pathology, and the expression
profile of α9∗−nAChR and α9 subunits in these cells remains
to be elucidated. Last, nAChR subtypes respond differently to
nicotine and at different concentrations. Although the range
of non-toxic, but behaviorally-relevant doses of nicotine that
can be studied in mice or other animals in vivo is limited, use
of other agents selective for particular nAChR subtypes could
help elucidate their contributions to inflammatory and immune
responses.
In summary, our observations motivate strategies involving
nAChR subtype-selective compounds to modulate responses
involved in inflammatory diseases. Recognizing that much more
work is to be done before applying our findings to human disease
conditions, we think that therapeutic possibilities are realistic
and proximal. For example, α9∗-nAChR of disease relevance
appear to be situated in peripheral immune cells, allowing for
design of ligands targeting them that would not be required
to penetrate to the brain, elevating the likelihood that adverse
side effects could be well-controlled. Moreover, there is limited
expression of α9∗-nAChR in other tissues (in olfactory epithelia
and the cochlea and in some skin cells; Jensen et al., 2005;
Lukas and Bencherif, 2006; Taly et al., 2009) relative to their
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rich expression in the immune system. Also, auditory function
in α9 KO animals (but not in α9/α10 DKO mice) is like that
in WT mice (Morley et al., 2017a), suggesting a low risk of
non-immune system side effects if α9∗-nAChR are modulated.
Nicotine itself is a therapeutic candidate, as it is likely to be much
safer delivered as a medicine than via use of tobacco products
and has very limited abuse liability on its own in humans (West
et al., 2000). There do seem to be links between elevated MS
susceptibility and progression and levels of tobacco cigarette
smoking (Handel et al., 2011), especially if smoking occurs in
adolescence (Salzer et al., 2013). However, other studies indicate
that nicotine actually could be protective in MS (Nizri et al.,
2009; Shi et al., 2009); as opposed to effects seen in cigarette
smokers, MS susceptibility seems to be reduced in users of snuff
(Hedström et al., 2009, 2013). Nicotine exposure does not equate
to cigarette smoking, which brings exposure to thousands of
other harmful compounds. Thus, all things considered, α9∗-
nAChR are viable targets for development of superior approaches
to block or control inflammation and immunity. On the other
hand, α7∗-nAChR activation could protect against inflammatory
and autoimmune insults if activated by α7∗-nAChR-selective
ligands. In the long term, findings from this and other studies
could alter clinical practice in the treatment of inflammatory and
autoimmune diseases, such as MS.
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